Medpace (NASDAQ:MEDP - Get Free Report) had its price target decreased by equities research analysts at Robert W. Baird from $340.00 to $313.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has a "neutral" rating on the stock. Robert W. Baird's target price would indicate a potential upside of 10.88% from the company's previous close.
Other equities research analysts also recently issued research reports about the company. Mizuho dropped their price objective on Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a report on Wednesday, April 9th. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a report on Monday, March 24th. William Blair reissued a "market perform" rating on shares of Medpace in a research report on Tuesday. TD Cowen downgraded Medpace from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $370.00 to $328.00 in a research note on Monday, April 14th. Finally, Leerink Partners initiated coverage on Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 target price for the company. Eleven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $352.60.
Check Out Our Latest Stock Analysis on MEDP
Medpace Price Performance
MEDP opened at $282.28 on Wednesday. The stock has a market capitalization of $8.53 billion, a P/E ratio of 22.35, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46. The company's 50 day simple moving average is $316.36 and its 200-day simple moving average is $332.53. Medpace has a one year low of $250.05 and a one year high of $459.77.
Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.06 by $0.61. The firm had revenue of $558.57 million for the quarter, compared to the consensus estimate of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same quarter in the prior year, the business earned $3.20 EPS. As a group, analysts anticipate that Medpace will post 12.29 EPS for the current year.
Institutional Trading of Medpace
Institutional investors have recently made changes to their positions in the business. Barclays PLC increased its stake in Medpace by 71.9% in the 3rd quarter. Barclays PLC now owns 19,781 shares of the company's stock valued at $6,603,000 after buying an additional 8,275 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Medpace in the third quarter valued at about $1,503,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Medpace in the third quarter valued at about $175,000. Tidal Investments LLC raised its holdings in Medpace by 257.9% during the third quarter. Tidal Investments LLC now owns 3,654 shares of the company's stock worth $1,220,000 after acquiring an additional 2,633 shares in the last quarter. Finally, Franklin Resources Inc. boosted its position in Medpace by 19.4% during the third quarter. Franklin Resources Inc. now owns 188,141 shares of the company's stock valued at $66,508,000 after purchasing an additional 30,530 shares during the last quarter. Institutional investors own 77.98% of the company's stock.
About Medpace
(
Get Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
